Sunitinib for metastatic progressive phaeochromocytomas and paragangliomas: results from FIRSTMAPPP, an academic, multicentre, international, randomised, placebo-controlled, double-blind, phase 2 trial

临床终点 医学 舒尼替尼 安慰剂 无进展生存期 副神经节瘤 随机对照试验 临床试验 内科学 肿瘤科 外科 总体生存率 病理 癌症 替代医学
作者
Éric Baudin,Bernard Goichot,Alfredo Berruti,Julien Hadoux,Salma Moalla,Sandrine Laboureau,Svenja Nölting,Christelle de la Fouchardière,Tina Kienitz,Timo Deutschbein,Stefania Zovato,Laurence Amar,Magalie Haissaguerre,Henri J L M Timmers,Patricia Niccoli,Antongiulio Faggiano,Moussa Angokai,Livia Lamartina,Florina Luca,Deborah Cosentini
出处
期刊:The Lancet [Elsevier BV]
卷期号:403 (10431): 1061-1070 被引量:93
标识
DOI:10.1016/s0140-6736(23)02554-0
摘要

Background No randomised controlled trial has ever been done in patients with metastatic phaeochromocytomas and paragangliomas. Preclinical and first clinical evidence suggested beneficial effects of sunitinib. We aimed to evaluate the safety and efficacy of sunitinib in patients with metastatic phaeochromocytomas and paragangliomas. Methods FIRSTMAPPP is a multicentre, international, randomised, placebo-controlled, double-blind, phase 2 trial done at 14 academic centres across four European countries. Eligible participants were adults (aged ≥18 years) with sporadic or inherited progressive metastatic phaeochromocytomas and paragangliomas. Patients were randomly assigned (1:1) to receive either oral sunitinib (37·5 mg per day) or placebo. Randomisation was stratified according to SDHB status (mutation present vs wild type) and number of previous systemic therapies (0 vs ≥1). Primary endpoint was the rate of progression-free survival at 12 months according to real-time central review (Response Evaluation Criteria in Solid Tumours version 1.1). On the basis of a two-step Simon model, we aimed for the accrual of 78 patients, assuming a 20% improvement of the 12-month progression-free survival rate from 20% to 40%, to conclude that sunitinib is effective. Crossover from the placebo group was allowed. This trial is registered with ClinicalTrials.gov, number NCT01371201, and is closed for enrolment. Findings From Dec 1, 2011, to Jan 31, 2019, a total of 78 patients with progressive metastatic phaeochromocytomas and paragangliomas were enrolled (39 patients per group). 25 (32%) of 78 patients had germline SDHx variants and 54 (69%) had used previous therapies. The primary endpoint was met, with a 12-month progression-free survival in 14 of 39 patients (36% [90% CI 23–50]) in the sunitinib group. In the placebo group, the 12-month progression-free survival in seven of 39 patients was 19% (90% CI 11–31), validating the hypotheses of our study design. The most frequent grade 3 or 4 adverse events were asthenia (seven [18%] of 39 and one [3%] of 39), hypertension (five [13%] and four [10%]), and back or bone pain (one [3%] and three [8%]) in the sunitinib and placebo groups, respectively. Three deaths occurred in the sunitinib group: these deaths were due to respiratory insufficiency, amyotrophic lateral sclerosis, and rectal bleeding. Only the latter event was considered drug related. Two deaths occurred in the placebo group due to aspiration pneumonia and septic shock. Interpretation This first randomised trial supports the use of sunitinib as the medical option with the highest level of evidence for anti-tumour efficacy in progressive metastatic phaeochromocytomas and paragangliomas. Funding French Ministry of Health, through the National Institute for Cancer, German Ministry of Education and Research, and the German Research Foundation within the CRC/Transregio 205/2, EU Seventh Framework Programme, and a private donator grant.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
shiguang发布了新的文献求助10
1秒前
SciGPT的应助被科研小小怪采纳,获得10
3秒前
4秒前
11完成签到 ,获得积分20
4秒前
帅气老张完成签到,获得积分10
4秒前
5秒前
jesse2j2完成签到,获得积分10
5秒前
5秒前
小二郎的应助被Moon采纳,获得10
5秒前
6秒前
1825810246完成签到 ,获得积分10
6秒前
hamburger发布了新的文献求助10
6秒前
huanmo发布了新的文献求助30
7秒前
搜集达人的应助被shiguang采纳,获得10
7秒前
7秒前
斯文哑铃完成签到,获得积分10
8秒前
科研通AI6.3的应助被LCBR采纳,获得10
8秒前
传奇3的应助被寒冷的寄云采纳,获得20
8秒前
林自完成签到,获得积分10
9秒前
王知颖发布了新的文献求助10
9秒前
LILY完成签到,获得积分10
9秒前
9秒前
10秒前
XR发布了新的文献求助10
11秒前
正直无极完成签到,获得积分10
11秒前
Hello的应助被Winnie采纳,获得10
13秒前
Daria发布了新的文献求助10
13秒前
13秒前
徐徐发布了新的文献求助10
13秒前
13秒前
一一完成签到 ,获得积分10
14秒前
大个的应助被ylzzz采纳,获得10
14秒前
111发布了新的文献求助10
15秒前
111发布了新的文献求助10
15秒前
上官若男的应助被Orlando采纳,获得10
15秒前
15秒前
15秒前
16秒前
111发布了新的文献求助10
16秒前
16秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
Sex, Aging, and Death in a Medieval Medical Compendium: Trinity College Cambridge MS R.14.52, Its Texts, Language, and Scribe 500
高分子基功能界面水蒸发材料与应用研究 500
外场增强的水汽发电研究 500
基于结构调控的功能化水诱导发电材料与器件研究 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8189227
求助须知:如何正确求助?哪些是违规求助? 9576621
关于积分的说明 21849153
捐赠科研通 7787179
什么是DOI,文献DOI怎么找? 3435518
关于科研通互助平台的介绍 2559732
邀请新用户注册赠送积分活动 2482482